Nicholas Farrell, MD
Hematology & Oncology · Rockville, MDNPI 1821291477
Payments from drug & device makers
Across 216 payments — averaging $2047.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$229K
- Merck$51K
- Mirati Therapeutics, Inc.$50K
- Seagen Inc.$35K
- Astrazeneca UK Limited$26K
- Eli Lilly$23K
- plus $28K from 31 others
What the payments were for
- Food & beverage$1,98799%
- Education$231%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 16 | $228,763 |
| Merck | 43 | $51,453 |
| Mirati Therapeutics, Inc. | 17 | $50,075 |
| Seagen Inc. | 40 | $35,072 |
| Astrazeneca UK Limited | 8 | $26,337 |
| Eli Lilly | 4 | $22,794 |
| Genentech, Inc. | 12 | $20,108 |
| AstraZeneca(2 entities) | 15 | $3,306 |
| Janssen Research & Development, LLC | 6 | $1,672 |
| Verastem, Inc. | 1 | $1,250 |
| GSK | 6 | $183 |
| Daiichi Sankyo Inc. | 5 | $134 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $111 |
| Incyte Corporation | 5 | $110 |
| AbbVie | 3 | $97 |
| Eisai Inc. | 3 | $81 |
| Pfizer | 3 | $63 |
| E.r. Squibb & Sons, L.L.C. | 3 | $62 |
| Taiho Oncology, Inc. | 2 | $45 |
| Johnson & Johnson | 2 | $43 |
| AVEO Pharmaceuticals, Inc. | 1 | $37 |
| Bristol Myers Squibb | 1 | $32 |
| Pharmaessentia USA Corporation | 1 | $32 |
| Gilead | 2 | $32 |
| Bayer | 1 | $32 |
| Beigene USA, Inc. | 1 | $27 |
| Exelixis Inc. | 1 | $25 |
| Legend Biotech USA Inc. | 1 | $24 |
| Array Biopharma Inc | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| Genentech USA, Inc. | 1 | $22 |
| Stemline Therapeutics Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
| Puma Biotechnology, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
| Iovance Biotherapeutics, Inc. | 1 | $14 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
How this compares
$442,168 in reported general payments places this provider in the 80th percentile of 242 hematology & oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 23 | $323,553 |
| TagrissoOsimertinib Mesylate | 15 | $293,888 |
| RevlimidLenalidomide | 14 | $287,818 |
| ImbruvicaIbrutinib | 14 | $228,139 |
| BrukinsaZanubrutinib | 17 | $146,780 |
| GleevecImatinib Mesylate | 21 | $145,755 |
| DopteletAvatrombopag Maleate | 12 | $117,869 |
| XareltoRivaroxaban | 60 | $55,397 |
| EliquisApixaban | 41 | $50,964 |
| Abiraterone Acetate | 14 | $41,142 |
| Hydroxyurea | 29 | $894 |
| Letrozole | 27 | $627 |
| Bicalutamide | 12 | $441 |
| Warfarin Sodium | 16 | $288 |
| Prochlorperazine Maleate | 14 | $126 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $3,306 | $293,88815 claims |
| Bristol Myers SquibbRevlimid | $32 | $287,81814 claims |
| Beigene USA, Inc.Brukinsa | $27 | $146,78017 claims |
| NovartisGleevec | $228,763 | $145,75521 claims |
| Johnson & JohnsonXarelto | $43 | $55,39760 claims |
| PfizerEliquis | $63 | $50,96441 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 242 hematology & oncology providers in Maryland.
Other hematology & oncology in Rockville
- John WallmarkRockville$3.5M
- Manish AgrawalRockville$1.4M
- Shannon O'ConnorRockville$326K
- Robert KreitmanOlney$54.2M
- Ralph BocciaBethesda$12.1M
- Dan ZandbergBaltimore$9.9M
- Ani BalmanoukianBaltimore$6.6M
- Mark MarkowskiBaltimore$5.9M
- Giuseppe GiacconeBethesda$5.4M
- Ivana GojoBaltimore$5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.